Navigation Links
AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Date:9/5/2012

IRVINE, Calif., Sept. 5, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, will be a presenting company at the Rodman & Renshaw 14th Annual Healthcare and Global Investment Conference to be held in New York City from September 9 -11, 2012 at the Waldorf-Astoria.  Mark Selawski, CFO of AtheroNova, will present at 3:15pm ET on Tuesday, September 11.

Mr. Selawski will discuss exciting near term milestones for AHRO-001, the Company's lead compound for the regression of atherosclerotic plaque, as well as the Company's pipeline and development plans. 

In addition to the presentation, Mr. Selawski will be available to meet with analysts, industry executives and investors in one-on-one meetings.  Those interested in meeting with Mr. Selawski for a one-on-one discussion during the Conference are encouraged to contact the Company directly at info@atheronova.com.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits.  The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the Company's pipeline, milestones and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AtheroNova Releases 2011 Financial Results
2. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
3. AtheroNova Announces a New Board Member
4. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
5. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
6. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
7. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
8. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
9. Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
10. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):